

DAFTAR PUSTAKA

- Ae, R., Sasahara, T., Yoshimura, A., Kosami, K., Hatakeyama, S., Sasaki, K., Kimura, Y., Akine, D., Ogawa, M., Hamabata, K., & Cui, L. (2021). Prolonged carriage of ESBL-producing Enterobacterales and potential cross-transmission among residents in geriatric long-term care facilities. *Scientific Reports*, 11(1), 21607. <https://doi.org/10.1038/s41598-021-01190-w>
- Alkan, S., Balkan, I. I., Surme, S., Bayramlar, O. F., Kaya, S. Y., Karaali, R., Mete, B., Aygun, G., Tabak, F., & Saltoglu, N. (2024). Urinary tract infections in older adults: Associated factors for *Extended-Spectrum Beta-Lactamase* production. *Frontiers in Microbiology*, 15, 1384392. <https://doi.org/10.3389/fmicb.2024.1384392>
- Amelia, A., Nugroho, A., & Harijanto, P. N. (2016). Diagnosis and management of infections caused by Enterobacteriaceae producing extended-spectrum β -lactamase. *Acta Medica Indonesiana*, 48(2), 156–166.
- Asmarawati, T. P., Widyatama, F. S., Notobroto, H. B., Nasronudin, Sugai, M., & Kuntaman. (2025). Risk factors and clinical impact of *Extended-Spectrum Beta-Lactamase* (ESBL)-producing *Escherichia coli* bacteremia among hospitalized patients. *Antibiotics*, 14(9), 882. <https://doi.org/10.3390/antibiotics14090882>
- Bajpai, T., Pandey, M., Varma, M., & Bhatambare, G. S. (2017). Prevalence of TEM, SHV, and CTX-M beta-lactamase genes in the urinary isolates of a tertiary care hospital. *Avicenna Journal of Medicine*, 7(1), 12–16. <https://doi.org/10.4103/2231-0770.197508>
- Basavaraju, M., & Shivanna, G. B. (2022). *Escherichia coli: An overview of main characteristics*. In M. Starčič Erjavec (Ed.), *Escherichia coli*. IntechOpen. <https://doi.org/10.5772/intechopen.105508>
- bioMérieux. (2013). *VITEK® 2 systems: Product information/operator's manual*. bioMérieux.
- Biutifasari, V. (2018). Extended spectrum beta-lactamase (ESBL). *Oceana Biomedicina Journal*, 1(1), 1–11. <https://doi.org/10.30649/obj.v1i1.3>
- Castanheira, M., Simner, P. J., & Bradford, P. A. (2021). Extended-spectrum β -lactamases: An update on their characteristics, epidemiology and detection. *JAC-Antimicrobial Resistance*, 3(3), dlab092. <https://doi.org/10.1093/jacamr/dlab092>

- Clinical and Laboratory Standards Institute. (2024). *Performance standards for antimicrobial susceptibility testing* (34th ed.). Clinical and Laboratory Standards Institute.
- Dewi, M. S., Prasetyo, R. V., Tirthaningsih, N. W., & Puspitasari, D. (2021). Profil pasien infeksi saluran kemih pada anak di Puskesmas Surabaya periode Januari–Desember 2018. *Jurnal Ilmiah Ilmu Kesehatan*, 9(1), 187–196.
- Donsu, J. D. T. (2016). *Metodologi penelitian keperawatan*. Pustaka Baru Press.
- Effendi, M. H., Tyasningsih, W., & Yurianti, Y. A. (2021). Presence of multidrug resistance (MDR) and *Extended-Spectrum Beta-Lactamase* (ESBL) of *Escherichia coli* isolated from cloacal swabs of broilers in several wet markets in Surabaya, Indonesia. *Biodiversitas*, 22(1), 304–309. <https://doi.org/10.13057/biodiv/d220137>
- Geleta, D., Abebe, G., Alemu, B., Workneh, N., & Beyene, G. (2024). Mechanisms of bacterial drug resistance with special emphasis on phenotypic and molecular characterization of extended spectrum beta-lactamase. *The New Microbiologica*, 47(1), 1–14.
- Gharavi, M. J., Zarei, J., Roshani-Asl, P., Yazdanyar, Z., Sharif, M., & Rashidi, N. (2021). Comprehensive study of antimicrobial susceptibility pattern and extended spectrum beta-lactamase (ESBL) prevalence in bacteria isolated from urine samples. *Scientific Reports*, 11, 578. <https://doi.org/10.1038/s41598-020-79791-0>
- Hrovat, K., Molan, K., Seme, K., & Ambrožič Avguštin, J. (2024). Molecular characterization of extended-spectrum β -lactamase-producing *Escherichia coli* isolated from lower respiratory tract samples between 2002 and 2019 in the Central Slovenia region. *Annals of Clinical Microbiology and Antimicrobials*, 23(1), 6. <https://doi.org/10.1186/s12941-023-00664-1>
- Husna, A., Rahman, M. M., Badruzzaman, A. T. M., Sikder, M. H., Islam, M. R., Rahman, M. T., Alam, J., & Ashour, H. M. (2023). Extended-spectrum β -lactamases (ESBL): Challenges and opportunities. *Biomedicines*, 11(11), 2937. <https://doi.org/10.3390/biomedicines11112937>
- Irfani, Q. I., Sari, D. K., Purbaningsih, D., Wibawa, T., & Nuryastuti, T. (2021). Urinary tract infection caused by *Extended-Spectrum Beta-Lactamase*-producing Enterobacteriaceae: A case series. *Journal of Clinical Microbiology and Infectious Diseases*, 1(1), 11–15. <https://jcmid.id/index.php/JCMID/article/view/2>
- Juanda, L. S., Girsang, E., & Nasution, S. L. R. (2024). Analisis faktor risiko pada infeksi *Escherichia coli* penghasil *Extended-Spectrum Beta-Lactamases*. *eJournal Kedokteran Indonesia*, 12(3), 264–272. <https://ejki.fk.ui.ac.id/index.php/journal/article/view/878>

- Kandarini, Y., Mahadita, W., & Marciyasa, P. A. (2020). Profil kuman pada infeksi saluran kemih di Rumah Sakit Umum Pusat Sanglah Bali tahun 2019–2020. *Jurnal Penyakit Dalam Udayana*, 4(2), 45–52. <https://doi.org/10.36216/jpd.v4i2.140>
- Kettani Halabi, M., Lahlou, F. A., Diawara, I., El Adouzi, Y., Marnaoui, R., Benmessaoud, R., & Smyej, I. (2021). Antibiotic resistance pattern of extended spectrum beta lactamase producing *Escherichia coli* isolated from patients with urinary tract infection in Morocco. *Frontiers in Cellular and Infection Microbiology*, 11, 720701. <https://doi.org/10.3389/fcimb.2021.720701>
- Kranz, J., Bartoletti, R., Bruyère, F., Cai, T., Geerlings, S., Köves, B., Schubert, S., Pilatz, A., Veeratterapillay, R., Wagenlehner, F. M. E., Bausch, K., Devlies, W., Horváth, J., Leitner, L., Mantica, G., Mezei, T., Smith, E. J., & Bonkat, G. (2024). European Association of Urology guidelines on urological infections: Summary of the 2024 guidelines. *European Urology*, 86(1), 27–41. <https://doi.org/10.1016/j.eururo.2024.03.035>
- KSM/Laboratorium RSUP Prof. Dr. I.G.N.G. Ngoerah. (2024). *Pola kepekaan mikroorganisme RSUP Prof. Dr. I.G.N.G. Ngoerah*. RSUP Prof. Dr. I.G.N.G. Ngoerah.
- KSM Obstetri dan Ginekologi dan KSM Anak RSUP Sanglah Denpasar. (2022). *Panduan praktik klinis KSM Obstetri dan Ginekologi dan KSM Anak*. RSUP Sanglah Denpasar.
- Liu, H., Qiu, S., Chen, M., Lyu, J., Yu, G., & Xue, L. (2022). A clinical prediction tool for extended-spectrum β -lactamase-producing Enterobacteriaceae urinary tract infection. *BMC Infectious Diseases*, 22, 50. <https://doi.org/10.1186/s12879-022-07040-y>
- Mahon, C. R., & Lehman, D. C. (2019). *Textbook of diagnostic microbiology* (6th ed.). Elsevier Saunders.
- Maldin, S. A. (2022). Teknik pengumpulan data dan analisis data. In *Metode penelitian kuantitatif*. Sanabil.
- Medina-Polo, J., Naber, K. G., Bjerklund Johansen, T. E., Cai, T., Koves, B., Bonkat, G., & Wagenlehner, F. M. E. (2021). Healthcare-associated urinary tract infections in urology. *GMS Infectious Diseases*, 9, Doc16. <https://doi.org/10.3205/id000074>
- Montelin, H., Camporeale, A., Hallgren, A., Angelin, M., Högvall, J., Östholm Balkhed, Å., Vading, M., Giske, C. G., Tängdén, T., & Swedish ESBL Study Group. (2024). Treatment, outcomes and characterization of pathogens in urinary tract infections caused by ESBL-producing

Enterobacterales: A prospective multicentre study. *Journal of Antimicrobial Chemotherapy*, 79(3), 531–538. <https://doi.org/10.1093/jac/dkad402>

- Prasetya, Y. A. (2018). Deteksi gen SHV pada isolat klinik *Escherichia coli* penghasil extended spectrum beta-lactamases dengan metode polymerase chain reaction dari urin pasien di RSUD Dr. Soetomo Surabaya. *AL-KAUNIYAH: Journal of Biology*, 11(2), 91–98. <https://doi.org/10.15408/kauniyah.v11i2.5779>
- Pratama, A. S., Djide, M. N., & Massi, M. N. (2019). Identifikasi genotip CTX-M pada *Escherichia coli* penghasil extended spectrum beta lactamase (ESBL) yang resisten pada cephalosporin generasi III di RSUP Wahidin Sudirohusodo Makassar. *Majalah Farmasi dan Farmakologi*, 5–9.
- Primeau, C. A., Bharat, A., Janecko, N., Carson, C. A., Mulvey, M., Reid-Smith, R., McEwen, S., McWhirter, J. E., & Parmley, E. J. (2022). Integrated surveillance of *Extended-Spectrum Beta-Lactamase* (ESBL)-producing *Salmonella* and *Escherichia coli* from humans and animal species raised for human consumption in Canada from 2012 to 2017. *Epidemiology and Infection*, 151, e14. <https://doi.org/10.1017/S0950268822001509>
- Puspandari, N., Sunarno, Febrianti, T., Febriyana, D., Saraswati, R. D., Rooslamati, I., Amalia, N., Nursofiah, S., Hartoyo, Y., Herna, Mursinah, Muna, F., Aini, N., Risniati, Y., Dhewantara, P. W., Allamanda, P., Wicaksana, D. N., Sukoco, R., Efadeswarni, ... Matheu, J. (2021). Extended spectrum beta-lactamase-producing *Escherichia coli* surveillance in the human, food chain, and environment sectors: Tricycle project pilot in Indonesia. *One Health*, 13, 100331. <https://doi.org/10.1016/j.onehlt.2021.100331>
- Rahme, D., Nakkash Chmaisse, H., & Salameh, P. (2025). Unraveling the length of hospital stay for patients with urinary tract infections: Contributing factors and microbial susceptibility. *Antibiotics*, 14(4), 421. <https://doi.org/10.3390/antibiotics14040421>
- Ramatla, T., Mafokwane, T., Lekota, K., Monyama, M., Khasapane, G., Serage, N., Nkhebenyane, J., Bezuidenhout, C., & Thekisoe, O. (2023). “One Health” perspective on prevalence of co-existing extended-spectrum β -lactamase (ESBL)-producing *Escherichia coli* and *Klebsiella pneumoniae*: A comprehensive systematic review and meta-analysis. *Annals of Clinical Microbiology and Antimicrobials*, 22(1), 88. <https://doi.org/10.1186/s12941-023-00638-3>
- Rastuti, M. R., Budayanti, N. N. S., & Dwija, I. B. N. P. (2023). Various types of extended spectrum β -lactamases: A literature review. *Journal of Clinical Microbiology and Infectious Diseases*, 3(2), 29–34. <https://doi.org/10.51559/jcmid.v3i2.52>

- Romyasamit, C., Sornsenee, P., Kawila, S., & Saengsuwan, P. (2024). *Extended-Spectrum Beta-Lactamase-producing Escherichia coli* and *Klebsiella pneumoniae*: Insights from a tertiary hospital in Southern Thailand. *Microbiology Spectrum*, 12(7), e0021324. <https://doi.org/10.1128/spectrum.00213-24>
- Shamsrizi, P., Gladstone, B. P., Carrara, E., Luise, D., Cona, A., Bovo, C., & Tacconelli, E. (2020). Variation of effect estimates in the analysis of mortality and length of hospital stay in patients with infections caused by bacteria-producing *Extended-Spectrum Beta-Lactamases*: A systematic review and meta-analysis. *BMJ Open*, 10(1), e030266. <https://doi.org/10.1136/bmjopen-2019-030266>
- Sikora, A., Zahra, F. (2023). Nosocomial Infections. In StatPearls. StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK559312/>
- Sora, V. M., Meroni, G., Martino, P. A., Soggiu, A., Bonizzi, L., & Zecconi, A. (2021). Extraintestinal pathogenic *Escherichia coli*: Virulence factors and antibiotic resistance. *Pathogens*, 10(11), 1355. <https://doi.org/10.3390/pathogens10111355>
- Sugiyono. (2019). *Metode penelitian kuantitatif, kualitatif, dan R&D* (Edisi ke-2, Cetakan ke-1). Bandung: Alfabeta.
- Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., Clancy, C. J., & Infectious Diseases Society of America Antimicrobial-Resistant Gram-Negative Infections Guidance Panel. (2024). Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. *Clinical Infectious Diseases*. <https://doi.org/10.1093/cid/ciae403>
- Whelan, S., Lucey, B., & Finn, K. (2023). Uropathogenic *Escherichia coli* (UPEC)-associated urinary tract infections: The molecular basis for challenges to effective treatment. *Microorganisms*, 11(9), 2169. <https://doi.org/10.3390/microorganisms11092169>
- Wijaya, C., Eriata, A. H., Rustawan, I. N. T., Candra, I. K. B. A., & Budayanti, N. N. S. (2023). Prevalence of uropathogen producing extended spectrum beta lactamase (ESBL) at urinary tract infection in chronic kidney disease patients. *Journal of Clinical Microbiology and Infectious Diseases*, 3(1), 12–15. <https://doi.org/10.51559/jcmid.v3i1.29>
- Zhou, Y., Zhou, Z., Zheng, L., Gong, Z., Li, Y., Jin, Y., Huang, Y., & Chi, M. (2023). Urinary tract infections caused by uropathogenic *Escherichia coli*: Mechanisms of infection and treatment options. *International Journal of Molecular Sciences*, 24(13), 10537. <https://doi.org/10.3390/ijms241310537>